Cardiovascular Drugs and Therapy

, Volume 21, Issue 4, pp 311–316 | Cite as

Predictors of Adherence to Statins for Primary Prevention

  • Devin M. MannEmail author
  • John P. Allegrante
  • Sundar Natarajan
  • Ethan A. Halm
  • Mary Charlson



Statins are potent drugs for reducing cholesterol and cardiovascular disease; however, their effectiveness is significantly compromised by poor adherence. This prospective study was designed to identify potentially modifiable patient factors including medication, disease, and diet beliefs related to statin adherence.


Veterans (n = 71) given their first prescription of a statin for primary prevention were interviewed at baseline, 3 months, and 6 months regarding medication, disease, and diet beliefs along with self-reported statin adherence.


At 6-month follow-up, 55% of the cohort was non-adherent with 10% reporting never having started their statin, 50% reporting misconceptions about the duration of treatment and a median use of <2 months among those who discontinued their statin. Multivariate predictors of non-adherence were expected short treatment duration (OR = 3.6, 1.4–9.4), low perceived risk of myocardial infarction (OR = 3.1, 1.1–8.7), concern about potential harm from statins (OR = 2.5, 1.0–6.3), being Hispanic (OR = 3.9, 1.0–15.2), and younger age (OR = 4.2, 1.1–15.8).


Poor adherence to statins was common in this primary prevention population with frequent early discontinuation despite access to low-cost medicines. Patient factors regarding the perception of risk, toxic effects of medication, expected treatment duration, as well as socio-demographic factors, were significant predictors of poor adherence and warrant further exploration.

Key words

adherence cardiovascular disease statins primary prevention predictor health beliefs 


  1. 1.
    Writing Group M, Rosamond W, Flegal K, et al. Heart disease and stroke statistics—2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;106:1799–818.Google Scholar
  2. 2.
    Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143.Google Scholar
  3. 3.
    Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Gotto J, Antonio M. The case for over-the-counter statins. Am J Cardiol 2004;94:753–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003;326:1423–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Caspard H, Chan AK, Walker AM. Determinants of the differences in LDL-cholesterol after initiation of statin treatment. Ann Pharmacother 2006;40:21–6.PubMedGoogle Scholar
  7. 7.
    Mitka M. Cardiologists like statins—more than patients do. JAMA 2001;286:2799–800.PubMedCrossRefGoogle Scholar
  8. 8.
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Morisky D, Ward H, Liu K. Self-reported medication taking behavior: a valid indicator for assessing compliance (abstract 26352). In: 129th meeting of the American Pharmacy Association. Atlanta; 2001.Google Scholar
  11. 11.
    Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004;38:1363–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Elder JP, Ayala GX, Harris S. Theories and intervention approaches to health-behavior change in primary care. Am J Prev Med 1999;17:275–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Leventhal H, Diefenbach M, Leventhal E. Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. Cogn Ther Res 1992;16.Google Scholar
  14. 14.
    Brewer N, Chapman G, Brownlee S, Leventhal E. Cholesterol control, medication adherence and illness cognition. Br J of Health Psychol 2002;7:433–47.CrossRefGoogle Scholar
  15. 15.
    Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of awareness of on-treatment patients about prescribed statins. Cardiovasc Drugs Ther 2004;18:399–404.PubMedCrossRefGoogle Scholar
  16. 16.
    Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. Arch Intern Med 2006;166:1855–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Aikens JE, Nease DE, Jr, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Annals Family Med 2005;3:23.CrossRefGoogle Scholar
  18. 18.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoecon 2004;22:13–33.Google Scholar
  22. 22.
    Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? J Gen Intern Med 2004;19:638–45.PubMedCrossRefGoogle Scholar
  23. 23.
    Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006;12:509–17.PubMedGoogle Scholar
  24. 24.
    Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther 2005;19:437–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Devin M. Mann
    • 1
    Email author
  • John P. Allegrante
    • 2
  • Sundar Natarajan
    • 3
  • Ethan A. Halm
    • 1
  • Mary Charlson
    • 4
  1. 1.Division of General Internal MedicineMount Sinai School of MedicineNew YorkUSA
  2. 2.Teachers College and Mailman School of Public HealthColumbia UniversityNew YorkUSA
  3. 3.Division of General Internal MedicineNew York University School of Medicine and the VA Medical CenterNew YorkUSA
  4. 4.Division of General Internal Medicine and Center for Complementary and Integrative, Weill Medical CollegeCornell UniversityNew YorkUSA

Personalised recommendations